Investors

Press Releases

Press Releases

Date	Title
May 8, 2020	Akebia Therapeutics to Present at RBC Capital Markets Global Healthcare Virtual Conference
May 5, 2020	Akebia Announced Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis; Reports First Quarter 2020 Financial Results
May 5, 2020	Akebia Therapeutics Announces Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis
May 4, 2020	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 28, 2020	Akebia Therapeutics to Report First Quarter 2020 Financial Results and Discuss Recent Business Highlights
April 7, 2020	Akebia Therapeutics Appoints Myles Wolf, M.D., M.M.Sc., Chief of Nephrology and Professor at Duke University School of Medicine, to Board of Directors
April 2, 2020	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 23, 2020	Akebia Therapeutics to Present Research at NKF 2020 Spring Clinical Meetings Live Virtual Conference
March 15, 2020	A Message from Akebia Therapeutics, Inc.’s Chief Executive Officer to Our Patients, Healthcare Providers, and Other Stakeholders During the Rapidly Evolving COVID-19 Pandemic:
March 10, 2020	Akebia Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Hosts Conference Call to Discuss Recent Business Highlights

Print Page

Email Page

Contact IR

Email Alerts

Tear Sheet

Akebia Therapeutics, Inc.
245 First Street, Suite 1400
Cambridge, MA 02142

Driving Directions

+1 617.871.2098 phone
+1 617.871.2099 fax